• English
    • العربية
  • العربية 
  • Login
  • QU
  • QU Library
  •  Home
  • Communities & Collections
  • Help
    • Item Submission
    • Publisher policies
    • User guides
    • FAQs
  • About QSpace
    • Vision & Mission
    • QSpace policies
Advanced Search
Advanced Search
View Item 
  •   Qatar University QSpace
  • Academic
  • Faculty Contributions
  • College of Arts & Sciences
  • Biological & Environmental Sciences
  • View Item
  • Qatar University QSpace
  • Academic
  • Faculty Contributions
  • College of Arts & Sciences
  • Biological & Environmental Sciences
  • View Item
  •      
  •  
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects

    Thumbnail
    Date
    2018
    Author
    Kaplan A.
    Abidi E.
    El-Yazbi A.
    Eid A.
    Booz G.W.
    Zouein F.A.
    Metadata
    Show full item record
    Abstract
    Diabetes is a global epidemic and a leading cause of death with more than 422 million patients worldwide out of whom around 392 million alone suffer from type 2 diabetes (T2D). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel and effective drugs in managing glycemia of T2D patients. These inhibitors gained recent clinical and basic research attention due to their clinically observed cardiovascular protective effects. Although interest in the study of various SGLT isoforms and the effect of their inhibition on cardiovascular function extends over the past 20�years, an explanation of the effects observed clinically based on available experimental data is not forthcoming. The remarkable reduction in cardiovascular (CV) mortality (38%), major CV events (14%), hospitalization for heart failure (35%), and death from any cause (32%) observed over a period of 2.6�years in patients with T2D and high CV risk in the EMPA-REG OUTCOME trial involving the SGLT2 inhibitor empagliflozin (Empa) have raised the possibility that potential novel, more specific mechanisms of SGLT2 inhibition synergize with the known modest systemic improvements, such as glycemic, body weight, diuresis, and blood pressure control. Multiple studies investigated the direct impact of SGLT2i on the cardiovascular system with limited findings and the pathophysiological role of SGLTs in the heart. The direct impact of SGLT2i on cardiac homeostasis remains controversial, especially that SGLT1 isoform is the only form expressed in the capillaries and myocardium of human and rodent hearts. The direct impact of SGLT2i on the cardiovascular system along with potential lines of future research is summarized in this review. - 2018, Springer Science+Business Media, LLC, part of Springer Nature.

    DOI/handle
    http://dx.doi.org/10.1007/s10741-017-9665-9
    http://hdl.handle.net/10576/12139
    Collections
    • Biological & Environmental Sciences [‎200 ‎ items ]

    entitlement


    QSpace is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU

     

     

    Home

    Submit your QU affiliated work

    Browse

    All of QSpace
      Communities & Collections Publication Date Author Title Subject Type Language
    This Collection
      Publication Date Author Title Subject Type Language

    My Account

    Login

    Statistics

    View Usage Statistics

    About QSpace

    Vision & Mission QSpace policies

    Help

    Item Submission Publisher policiesUser guides FAQs

    QSpace is a digital collection operated and maintained by the Qatar University Library and supported by the ITS department

    Contact Us | Send Feedback
    Contact Us | Send Feedback | QU